Targets › ZAP70
1 program from 1 company in 8 trials: 4 Phase 3, 4 Phase 2; Immunology; next expected readout Feb 2027.
Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. (UniProt, P43403)
Open in Phaseline: the race on ZAP70, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Zasocitinib TEC kinase inhibitor | TEC, ZAP70 | Phase 3 | Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa; Nonsegmental Vitiligo … | Feb 2027 |
Psoriatic Arthritis (3) Crohn's Disease (2) Plaque Psoriasis (1) Hidradenitis Suppurativa (1) Nonsegmental Vitiligo (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.